News | Stents Drug Eluting | February 19, 2018

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

Recently approved by FDA, the EluNIR drug-eluting stent opens clogged arteries to restore blood flow in tortuous anatomy of patients with coronary artery disease

 

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently became the first in Michigan to offer patients with coronary artery disease a new treatment option for vessels that are difficult to stent because of the size and intricacy.

Tamam Mohamad, M.D., chief of cardiology at DMC Detroit Receiving Hospital, treated 60-year-old Haila Alamri, the mother of nine children and an armful of grandchildren, who was experiencing angina, with pressure in her chest, after walking short distances. The symptoms caused her a lot of fear and anxiety and greatly affected her quality of life.

Mohamad completed the procedure guiding the newly U.S. Food and Drug Administration (FDA)-approved EluNIR stent through a complex, circuitous course of blood vessels to reach and open a main artery that was 90 percent blocked. The three-hour procedure brought the blockage to 0 percent, and Friday, Haila Alamri went home the next day.

The EluNIR drug-eluting stent has the narrowest strut width of any FDA-approved stent currently available in the U.S. This low-profile stent, with radiopaque spring tip, makes it easier to maneuver in heavily calcified or intricately curved blood vessels.

“At the DMC, we strive to provide our patients with the newest treatment options to best serve their cardiac needs,” said Mohamad. “It’s the same kind of care I would provide for my own family.”

Mahir Elder, M.D., director of endovascular medicine at the DMC Heart Hospital, added, “The DMC Cardiovascular team's goal is to stay on the forefront of technology. As leading physicians in the field, we strive to bring the latest and greatest technology and innovation to the metro Detroit community.”

Cardiovascular disease is the No. 1 killer in the United States. According to the American Heart Association, each day about 2,200 Americans die from cardiovascular disease, about one person every 40 seconds.

During Heart Month, the DMC Cardiovascular team recommends patients seek medical attention immediately if they are experiencing any of the following common symptoms of a heart attack:

  • Severe pressure, fullness, squeezing, pain or discomfort in the center of the chest that lasts for more than a few minutes;
  • Pain or discomfort that spreads to the shoulders, neck, arms or jaw;
  • Chest pain that gets worse;
  • Chest pain that does not get better with rest or by taking nitroglycerin;
  • Chest pain that happens along with any of these symptoms:
    • Sweating, cool, clammy skin, or paleness
    • Shortness of breath
    • Nausea or vomiting
    • Dizziness or fainting
    • Unexplained weakness or fatigue
    • Rapid or irregular pulse

Although chest pain is the key warning sign of a heart attack, it may be confused with other conditions. These include indigestion, pleurisy, pneumonia, tenderness of the cartilage that attaches the front of the ribs to the breastbone, and heartburn.

For more information: www.dmc.org

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Detroit Cardiogenic Shock Initiative Goes National at TCT 2017

DMC Heart Hospital Completes Complex High-Risk Indicated Interventional Procedure Course

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init